{'fraction_non_alphanumeric': 0.023076923076923078, 'fraction_numerical': 0.007692307692307693, 'mean_word_length': 5.454545454545454, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
AN ASSAY FOR ANTIBODIES TO HISTOCOMPATIBILITY ANTIGENS BASED ON INHIBITION OF RADIOIODINE‐LABELED ANTIBODY BINDING

SUMMARY This assay for antibodies to human histocompatibility antigens is both sensitive and rapid. It is based on the inhibition of binding of purified, radiolabeled alloantibody to donor lymphocytes by recipient serum. Labeled, purified, anti-HL-A IgG is prepared from monospecific histocompatibility typing sera or from pooled cytotoxic sera. The assay appears to be as much as 50-fold more sensitive than are current tests based on cytotoxicity. Hemodialysis, accompanied by transfusions at 9–30-day intervals, resulted in antibodies detectable by the binding inhibition assay, but not by cytotoxicity tests, in all patients on dialysis for more than 4 months.